Context: Adolescents with type 1 diabetes (T1D) have difficulty obtaining optimal glucose control, which may relate to insulin resistance (IR), especially during puberty. Moreover, IR increases the risk for cardiovascular disease, the leading cause of death in T1D. However, the tissue specificity of IR in adolescents with T1D has not been fully phenotyped.
childhood (1) (2) (3) . For example, youth with T1D have dyslipidemia, worse myocardial strain, and vascular stiffening compared with normoglycemic peers (2, 4, 5) . CVD is associated with insulin resistance (IR) in youths and adults with type 2 diabetes (T2D) (6, 7) . Moreover, obesity and metabolic syndrome are traditional risk factors for IR and CVD, and obesity is increasing in T1D (8) . However, we have previously demonstrated that even normal-weight adolescents and adults with T1D had more IR than controls without diabetes who had similar body mass index (BMI) (9) (10) (11) . Therefore, IR in T1D is not due to obesity alone.
A growing body of research implicates IR as a significant feature of T1D-related CVD (5, (11) (12) (13) (14) . IR in adults with T1D is associated with dyslipidemia, atherosclerosis, and CVD in general (11, 14, 15) . Notably, youth with T1D with higher insulin sensitivity relative to other youth with T1D have a CVD risk profile more similar to that of controls without diabetes (5) . We previously demonstrated that IR in adolescents with T1D is associated with exercise, cardiac, and vascular dysfunction, as well as a more atherogenic cholesterol subfraction profile (2, 10, 16) .
In adults, T2D is well characterized in terms of tissuespecific IR, and similar measures have been performed in adults with T1D (9, 11) . Adults with T1D have tissuespecific IR in the adipose, liver, and skeletal muscle (9, 11) . Youth-onset T1D increases the risk for complications due to the onset of metabolic dysfunction at a younger age (10) . Additionally, metabolism in youth differs from that in adults because of the impact of growth and the profound impact of pubertal IR, a time period where insulin sensitivity is half that seen in prepuberty or adulthood (17) . Therefore, studying T1D and IR in young populations is imperative to fully understanding how IR and CVD interact to affect youth with T1D. In 1993, Arslanian et al. (18) published a three-phase hyperinsulinemic euglycemic (HE) clamp study in a smaller cohort of youth with T1D. However, the study did not include a tracer to assess adipose IR, used fewer doses of insulin during the clamp, did not control diet or activity, and used insulin regimens that differ substantially from those currently used in youth, so the mean hemoglobin A1c (HbA1c) was very high.
Given the ability of new therapeutics to target IR in specific organs, elucidating tissue-specific targets for intervention in youth with T1D holds great potential. Therefore, we measured the effects of varied doses of hyperinsulinemia on lipolysis, endogenous glucose release, and stimulated peripheral glucose uptake in a larger group of adolescents with and without T1D on insulin delivery regimens and glycemic control typical of modern youth.
Participants and Methods

Participants
Adolescents with and without T1D were recruited from Children's Hospital Colorado and the Barbara Davis Center for Childhood Diabetes for one of two prospective, cross-sectional studies: RESistance to InSulin in T1D ANd T2D (RESISTANT) and Androgens and Insulin Resistance Study (AIRS) (2) . Inclusion criteria were BMI in the 10th to 99th percentiles and sedentary status to minimize effects of varying physical activity on insulin sensitivity (,3 hours of exercise/week, validated with a 3-day activity recall and 7 days of accelerometer use). Exclusion criteria were alanine aminotransferase (ALT) . 80 IU/mL; blood pressure . 140/90 mm Hg; hemoglobin , 9 mg/dL; serum creatinine . 1.5 mg/dL; smoking; medications affecting IR, blood pressure, or lipids; and, in youths with T1D, HbA1c , 12%. The University of Colorado AMC Institutional Review Board and the Clinical Translational Research Center Scientific Advisory Review Council approved the study. Informed consent was obtained from all participants age $ 18 years, and parental consent and participant assent was obtained for all participants age , 18 years.
Physical activity
A 3-day pediatric activity recall assessing metabolic equivalents was completed (19) , and participants wore an Actigraph GT3x accelerometer (Actigraph Corp., Pensacola, FL) for 7 days to assess habitual level of physical activity. Data collected were corrected for wear time and were categorized into the following age-appropriate activity levels: sedentary, light, lifestyle, moderate, vigorous, and very vigorous (20) .
Insulin sensitivity
To minimize confounding effects on insulin sensitivity, the study day was preceded by 3 days of restricted physical activity and a fixed weight-maintenance diet (55% carbohydrates, 30% fat, and 15% protein), performed in the follicular phase for female participants. Participants were admitted to the inpatient Clinical Translational Research Center for 12 hours of overnight monitored fasting. In participants with T1D, subcutaneous insulin was replaced with a variable-rate overnight intravenous insulin infusion to normalize blood glucose concentrations (100 mg/dL). The following morning, a four-phase HE clamp was performed (7, 10) to determine adipose, hepatic, and peripheral IR. After a 2-hour basal phase, during which the overnight insulin infusion was continued to maintain normoglycemia, insulin doses for each additional 1.5-hour phase were 10, 16, and 80 mU/m 2 /minute, based on our (7, 10, 21) and others' (7, 10, 21) experience with the higher insulin requirements in pubertal youth. Twenty percent dextrose (spiked with 6,6-2 H 2 glucose) was infused to maintain blood glucose at 95 mg/dL, checked every 5 minutes with bedside Yellow Springs Instrument glucose meter (Yellow Springs, OH). Glucose infusion rate was calculated from the steady-state measurements from the last 30 minutes of each phase.
Tracer infusion protocol
At 6 AM, blood samples to measure background enrichment and concentrations were obtained. Then, a bolus of 4.5 mg/kg 6,6-primed (1.6 mmol/kg), then constant (0.11 mmol/kg/minute), infusion of 2 H 5-glycerol. During the last 30 minutes of each of the four clamp phases, four samples, each 10 minutes apart, were drawn for glucose, glycerol, free fatty acid (FFA), and insulin concentrations and glucose and glycerol tracer enrichments (22) .
Sample analysis
2 H 5 glycerol and 6,6-2 H 2 glucose were analyzed by using gas chromatography-mass spectrometry as described (9, 22, 23 
Imagine techniques
Body composition was assessed by dual-energy x-ray absorptiometry to determine FFM (24) . Abdominal magnetic resonance imaging was performed with a 3-T magnet (GE, Milwaukee, WI). Visceral adiposity was measured by using the gold standard of a magnetic resonance imaging slice at lumbar vertebrae 4 and 5 (25) . Hepatic fat fraction was measured by using the modified Dixon method (26).
Tracer calculations
All isotopic enrichments were corrected for background enrichments. The glucose and glycerol rate of appearance (Ra), rate of disappearance (Rd), and metabolic clearance rate (MCR) over the last 30 minutes of each phase of the clamp were calculated by using the Steele non-steady-state equation, accounting for "spiked" glucose in the 20% dextrose infusion (9) . Glucose Rd is expressed as both mg/kg/min and mg/kg lean mass/min. Controlling overnight glycemia with an insulin infusion can lead to insulin concentrations, which may partially suppress endogenous glucose production (EGP) and glycerol Ra in the "basal" state. Thus, standard calculations of percentage suppression and IC50 cannot be used because they assume a nonsuppressed basal state. Instead, to describe changes in Ra across the different insulin concentrations of each phase, the intercept and slope of the regression line for each individual's data were also used to calculate the predicted Ra at the average insulin concentration for all participants during the 10-mU/m 2 / minute phase for glycerol Ra and the 16-mU/m 2 /minute phase for EGP (27) . Data were log-transformed before regression. However, negative glucose Ra values could not be logtransformed, and thus a constant just larger than the absolute value of the most negative Ra was added to all glucose Ra values. Data were reverse-transformed for presentation of model results. /minute phase MCR), body composition (visceral fat, liver fat, waist-to-hip ratio), inflammation (hs-CRP, IL-6) metabolic markers (adiponectin, leptin, HbA1c, and C-peptide) and activity were examined by using Spearman correlation coefficients.
Statistical analysis
By modeling the Ra from all clamp phases relative to the insulin concentration, we were able to best describe dynamic physiologic changes in Ra in each individual and overcome problems created by the need to control overnight glycemia. Repeated-measures mixed-effects models were used to compare outcomes measured at multiple time points during the clamp, with data log-transformed prior to modeling. The repeated-measures models for glucose and insulin contained terms for group (T1D or control), clamp phase, and the interaction of group and phase. For repeated-measures outcomes (EGP, glycerol Ra, glycerol, FFA) that could be affected by serum insulin concentrations, insulin was added to the model and the Akaike information criterion was used to test whether a random effect of insulin should be included (28) . The three-way interactions of group, phase, and insulin were tested for significance, but all two-way interactions were retained in the models. For each of the repeated-measures models, we examined the significance of all the terms in the models; however, the primary comparison of interest for each clamp variable was defined a priori as the least-squares difference between the patients with T1D and controls at the 10-mU/m 2 /minute phase and serum insulin concentration equal to the overall average at the 10-mU/m 2 /minute phase for glycerol Ra, glycerol, and FFA and the 16-mU/m 2 /minute phase and serum insulin concentration equal to the overall average at the 16-mU/m 2 /minute phase for EGP. P values , 0.05 were considered to indicate statistically significant differences for main effects; P values , 0.25 were considered to indicate significance for interactions. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Thirty-five youth with T1D and 22 youth without diabetes were enrolled (Table 1) . By design, the two groups had similar age, sex, Tanner stage, BMI and BMI percentile distributions, and physical activity data (including metabolic equivalents from the 3-day pediatric activity recall and the accelerometer data). The T1D group consisted of more white youth, reflecting the increased prevalence of the disease in white patients.
Body composition measures (including the waist-to-hip ratio; waist circumference; and percentage of visceral, liver, and total fat) were similar between groups, although lean mass was slightly higher in patients with T1D.
Leptin, adiponectin, HDL, and triglycerides did not differ between groups (Table 2) . However, total cholesterol (P = 0.049) and low-density lipoprotein cholesterol (P = 0.03) were lower in youth with T1D. The T1D group had a higher HbA1c (P , 0.0001), and the fasting C-peptide was higher in the control group, as expected (P , 0.0001). There were no differences in any markers of inflammation.
By design, the glucose concentration was steady throughout the phases and was similar between groups (Fig. 1A) . The insulin concentration (Fig. 1B) increased in both groups with the administration of increasing doses of insulin. Insulin differed between groups (P = 0.0011) across phases because of the increased insulin dose required during the basal phase in the T1D group to maintain normoglycemia. Glucose enrichment, expressed as the tracer-to-tracee ratio 2 background enrichment, is shown in Fig. 1C . EGP generally decreased with increases in the insulin dose; however, the observed EGP was higher in T1D during the 16-mU/m 2 /minute phase ( Fig. 1D ; P , 0.001), as was the predicted EGP at an insulin concentration of 55 mIU/mL; the values were slightly different than the raw EGP in Fig. 1D because they were calculated at 55 mIU/mL of insulin ( Fig. 1F ; P , 0.001), with incomplete suppression of glucose Ra in youth with T1D. The slopes of the lines to calculate Data are shown as mean 6 SD or as median (first, third quartiles).
Abbreviations: 3DPAR, 3-day physical activity recall; METs, metabolic units. In the repeated-measures model for EGP, the interaction of group and phase of the clamp was not significant (Table 3 ; P = 0.069), indicating that the groups were not significantly different regarding the change in EGP across all phases of the clamp. Glucose Rd differed between groups during the 80-mU/m 2 /minute phase, with and without adjustment for lean mass (376 15 mmol/kg/minute for the T1D group vs 61 6 5 mmol/ kg/minute for the control group and 53 6 21 mmol/kg lean mass/minute for the T1D group vs 92 6 7 mmol/kg lean mass/minute for the control group; P , 0.001 for both). MCR tended to increase with each increase in insulin dose but was lower in the youths with T1D during the 80-mU/m 2 /minute phase ( Fig. 1E ; P , 0.0001);results were similar if MCR was calculated with a lean body mass (P , 0.0001). FFA concentrations decreased with increasing insulin doses but were higher in patients with T1D at the 10-mU/ m 2 /minute phase ( Fig. 2A ; P , 0.0001). Glycerol also decreased per phase, but it was higher in the T1D group at the 10-mU/m 2 /minute phase ( Fig. 2B ; P , 0.0001). Glycerol enrichment, expressed as the tracer-to-tracee ratio-background enrichment, is shown in Fig. 2C .
Glycerol Ra was more suppressed in the 10-mU/m 2 / minute phase in controls than the T1D group ( Fig. 2D ; P , 0.0001); similarly, predicted glycerol Ra was higher in patients with T1D, with the values slightly different than the raw glycerol Ra in Fig. 1D because they were calculated at 53 mIU/mL of insulin ( Fig. 2E ; P = 0.019). The slopes to calculate predicted glycerol RA between controls and patients with T1D were different [median slopes were 20.33 (20.43, 20.25) in the control group vs 20.20 (20.34, 20 .04) in the T1D group; P = 0.017], whereas the intercepts were not [medians of 2.36 (1.67, 2.70) in controls vs 1.92 (1.11, 2.45) in patients with T1D; P = 0.112]. In the repeated-measures models for glycerol Ra, glycerol, and FFA, the interactions of group and phase of the clamp were significant (Table 3 ; P = 0.0005, P , 0.0001, P , 0.0001, respectively), indicating significantly different trajectories between groups across the phases of the clamp. Furthermore, the least-squares means of glycerol Ra, glycerol, and FFA were all significantly higher in the T1D group than in the control group at the 10-mU/m 2 /minute phase (Table 4 ; P = 0.0005, P = 0.0002, P , 0.0001, respectively).
For the entire cohort, glucose Rd had a negative correlation with EGP at the 16-mU/m 2 /minute phase (P = 0.004). In youth with T1D, we found that MCR correlated with FFA at the 80-mU/m 2 /minute phase (Table 4 ; P = 0.005), IL-6 (P = 0.012), hs-CRP (P = 0.001), and leptin (P = 0.008). We also found that glycerol Ra correlated with IL-6 (P = 0.035) and white blood cell count We modeled EGP, glycerol Ra, glycerol, and FFA concentrations, controlling for the phase and the insulin concentration at each phase (Table 3 ). The two-way interactions in the model can be interpreted as follows: (1) T1D*phase is the difference in the effect of each phase compared with the reference phase (phase 80) for a participant in the T1D group compared with the control group; (2) insulin*phase is the difference in the effect of insulin at each phase compared with the reference phase (phase 80) for both groups combined; and (3) insulin*T1D is the difference in the effect of insulin for the T1D group compared with the control group. The main effects of T1D, insulin, and phase cannot be interpreted directly in a model with interactions. The least-squares estimate (bottom row of Table 3 ) is the estimated difference in the outcome between the groups at the phase of interest (16-mU/m 2 /minute phase for glucose Ra and 10-mU/m2/minute phase for all other outcomes), adjusting for the mean insulin value at that phase. The groups were significantly different for EGP, glycerol Ra, glycerol, and FFA (P , 0.001).
Discussion
By using a four-phase HE clamp, with insulin dosages that specifically target adipose, liver, and peripheral/ muscle tissues, in combination with glucose and glycerol isotope tracers, our study comprehensively yet precisely characterized tissue-specific metabolic abnormalities in youth with T1D compared with well-matched controls. Overall, we found that T1D youth had significantly lower peripheral, hepatic, and adipose insulin sensitivity compared with youth without diabetes, despite a lack of traditional markers of the metabolic syndrome and IR, such as low HDL cholesterol or adiponectin or high triglycerides, ALT, or hepatic or visceral fat.
Our findings of peripheral IR in youth with T1D confirm our previous work in another cohort of similarly-aged youth and that by other groups (10, 18) . This peripheral IR may in part be due to muscle mitochondrial dysfunction, which we have demonstrated in a similar cohort; the lower rate of muscle oxidative phosphorylation correlated with peripheral IR (29) . The relationship between peripheral IR and muscle mitochondrial abnormalities has been well described in other states, such as T2D, aging, and burns, and it appears that this relationship also exists in T1D (17, 20, 30) . Likewise, we found that peripheral IR correlated with adipose IR and markers of inflammation (FFA in the 80 mU/m 2 /minute phase, IL-6, and hs-CRP) in the adolescents with T1D, as has been seen in populations with T2D (7). Elevated FFA levels induce muscle IR and vascular dysfunction. Vascular dysfunction of any kind, which we and others have shown to be present in adolescents with T1D, can also decrease muscle blood flow and secondarily nutrient and/or insulin delivery to muscle and could induce mitochondrial dysfunction and IR (24, 31) . In summary, increased FFA levels and vascular and/or mitochondrial defects may all contribute to muscle IR in T1D.
We also found that hepatic EGP did not suppress in response to insulin in youth with T1D, regardless of method of calculation, even during systemic insulin concentrations in excess of 200 mU/mL. Because of the influence of glucose concentrations in the interpretation and measurement of basal EGP, we chose to control overnight blood glucose concentrations (27) . This led to significantly greater insulin concentrations during the basal phase in participants with diabetes. Similar findings were observed in a smaller clamp study in youth with T1D (18) . Therefore, in this cohort of patients we also applied modeling techniques that are less reliant on measurements obtained during the basal phase, rather than using percentage suppression of basal or IC50 (32) . By modeling the EGP from all clamp phases relative to the insulin concentration, we were able to best describe dynamic physiologic changes in EGP in each individual. On the basis of our models for predicted EGP, which use the EGP and insulin concentrations at all phases for each individual, at a serum insulin concentration of 55 mU/ mL, the glucose Ra in a participant with diabetes would be more than double that seen in a control. Similar findings have been described in adults with T1D (9, 18) , with a single limited study in youth with T1D, suggesting that this hepatic phenomenon occurs early in the pathology of T1D (18) .
There are several possible reasons as to why youth with T1D have persistent EGP during hyperinsulinemia, including lack of portal insulin and/or excess glucagon. Interestingly, despite having hepatic IR, akin to people with T2D, our youth with T1D lacked the elevations in hepatic or visceral fat seen in T2D. The most likely explanation is the lack of portal insulin delivery, with a relative hepatic insulin deficiency despite peripheral hyperinsulinemia. Normally, over a third of pancreatic-secreted insulin is cleared from the portal circulation by the liver before release into the periphery (33) . Subcutaneous insulin injections, insulin pumps, and our delivery via a peripheral intravenous route did not mimic portal delivery. Formulas to estimate portal insulin concentration and insulin clearance do exist; however, they have not been fully tested in youth with and without diabetes. This would be worthy of further research. Additionally, there may be a failure of suppression of glucagon secretion because of a lack of a paracrine effect of insulin from b cells on the a cells in the pancreas, or other causes of a-cell dysfunction (34) . Glucagon secretion can be controlled by adding somatostatin to a clamp, which suppresses pancreatic insulin and glucagon secretion (35) . However, we were unable to use this method in youth and did not collect serum for measurement of glucagon.
Because there is known a cell dysfunction in T1D, it is possible that not all EGP is due to hepatic IR, and some excess glucagon is contributing to the EGP. Future work is needed to determine the role of glucagon in elevated endogenous glucose release in T1D.
In addition to abnormalities in glucose metabolism, youth with T1D also have evidence of adipose IR. We found that FFA and glycerol concentrations were higher during all phases of the clamp in the group with T1D. The glycerol tracer results indicate that these differences are due to inadequate suppression of lipolysis, and indeed predicted glycerol Ra was suppressed ;60% more in controls, with no difference in glycerol clearance. Glycerol was selected as a tracer because the majority of glycerol is taken up by the liver and thus serum glycerol falls into a one-pool model. FFA can functionally be used as a fat metabolism marker but can also be re-esterified within the adipose cell and taken up by multiple tissues, leading to the need for more complex modeling with multiple tracers to assess lipolysis. However, the FFA and glycerol results both displayed similar rates of suppression in our study. This suggests that alterations in reesterification or FFA uptake rates, which would cause FFA results to diverge from glycerol Ra results, are perhaps not different in youth with diabetes; thus, both may reflect adipose IR with increased lipolysis. This confirms previous work with only FFA as a measure of adipose IR in youth with T1D (18) .
It is unclear why youth with T1D have adipose IR. Hyperglycemia has been shown to induce inflammation, which is thought to influence IR (36). Although we did not find increased generalized serum markers of inflammation (aspartate aminotransferase, ALT, IL-6, white blood cell count, platelets, or hs-CRP) in T1D, glycerol Ra did positively correlate with IL-6, suggesting a link requiring further investigation, although serum samples may not be truly representative of tissue inflammation. Additionally, other hormones, such as epinephrine, glucagon, and glucagon-like peptide-1, can affect the apparent response of lipolysis to insulin (34, 37, 38) . Future work should include the measure of these hormones to determine whether their dysregulation contributes to persistent lipolysis.
Our study had several strengths and weaknesses. Our cohort was larger than in previous studies in youth with T1D and was under better glycemic control; we also added control for diet and activity, additional insulin phases during the clamp, used a glycerol tracer, and avoided hypoglycemic episodes in the early morning, which can induce counter-regulatory hormones, specifically elevated growth hormone (18) . Another strength of our study is the use of the gold standard HE clamp and the use of glucose and glycerol tracers to directly measure adipose and hepatic IR. We also carefully controlled for BMI, stage of menstrual cycle, and pubertal stage and admitted the participants overnight to control glycemia and a fasting period, factors known to influence IR. One limitation is that our T1D group consisted of more white patients, but this reflects the T1D population; if anything, it would bias our results to not finding IR. We also could not perform a somatostatin pancreatic clamp because of the pediatric age group, and we did not collect samples for glucagon.
Conclusion
We found that youth with T1D have profound multiorgan IR, including adipose, hepatic, and muscle tissue, without features of the metabolic syndrome. This IR occurs regardless of obesity but may be worsened by the rising rates of obesity in T1D. The IR we demonstrated may contribute to the early onset of CVD in youth with T1D and could be a therapeutic target needing further research.
Author Contributions: M.C.G researched and analyzed data and wrote and edited the manuscript; J.J.S. performed statistical analysis and wrote and edited the manuscript; J.T. performed statistical analysis and edited the manuscript; B.C.B, G.V.C., A.D.B., S.B., and A.S. researched data and edited the manuscript; L.P. performed statistical analysis and edited the manuscript; K.J.N. designed the study, researched and analyzed data, contributed to discussion, and edited the manuscript.
Correspondence and Reprint Requests: Melanie CreeGreen, MD, PhD, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, P.O. Box 265, 13123 East 16th Avenue, Aurora, Colorado 80045. E-mail: Melanie. green@childrenscolorado.org.
Disclosure Summary: The authors have nothing to disclose.
